Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12845762 | 1.00 | LMNA (0.53) | LMNATDP1 | |
| SCHEMBL6835457 | 1.00 | LMNA (0.53) | LMNATDP1 | |
| SCHEMBL7050768 | 0.88 | LMNA (0.70) | LMNA | |
| SCHEMBL14334595 | 0.88 | LMNA (0.70) | LMNA | |
| SCHEMBL16976211 | 0.88 | LMNA (0.70) | LMNA | |
| SCHEMBL7764898 | 0.83 | LMNA (0.64) | LMNA | |
| SCHEMBL8741593 | 0.83 | LMNA (0.49) | LMNA | |
| SCHEMBL8978138 | 0.82 | LMNA (0.62) | LMNA | |
| SCHEMBL9260881 | 0.82 | LMNA (0.62) | LMNA | |
| SCHEMBL20468079 | 0.81 | LMNA (0.60) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975021-B1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2017-07-26 | — | — | EP | disclosed |
| EP-1353899-B1 | A PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975021-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | Bracco Imaging SPA (IT) | 2016-01-20 | — | — | EP | disclosed |
| US-20040082812-A1 | Process for the preparation of iopamidol and the new intermediated therein | BRACCO IMAGING S.P.A. (IT) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082812-A1 | Process for the preparation of iopamidol and the new intermediated therein | INSR, ACVRL1, CBR3 | LMNA 1132/4885TDP1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.